Research to identify new prognostic biomarkers, which are associated with outcome measures, as well as predictive biomarkers, which predict response or resistance to therapy is ongoing.
Butere results presented better specificity measures as well as positive predictive value, while Nyalenda had an outlier (measles) in the specificity measures.
These models have been compared using measures such as predictive power (R), predictive mean and residual mean squared error (RMSE).
IL-18 is a key cytokine regulator of this balance that, among other clinical and cytokine measures, stands out as predictive of organ dysfunction and adverse outcomes after CPB [ 2].
The accuracy measured as "Positive Predictive Value" (PPV) in statistical terms is defined as the ratio TP/ TP+FP), where TP is the number of true positives and FP is the number of false positives [30], [31].
This possibility, however, was not measured as a predictive factor in this study.
Changes in tumour choline were not measured, as the predictive utility of the technique had not been established in the literature at the time of study design.
Practice, patient age, sex and Townsend score (a postcode based deprivation measure) were identified as predictive of response, with higher response related to older age, being female and living in an area with a lower Townsend score (less deprived).
